Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Christopher J. Sweeney(The University of Adelaide), Margaret McJannett(University of Alberta), Sonia Yip(The University of Sydney), M. Neil Reaume(The University of Melbourne), Francisco Vera-Badillo(Queen's University), Andrew Martin(Clinica Universidad de Navarra), Robert Blum(Universitätsklinikum Würzburg), Diana Winter(The University of Sydney), Bala Renuka Chittajallu, Elizabeth Hovey, Patricia Bastick(Port Macquarie Base Hospital), Michelle R. Cronk, Anthony Dowling(Monash University), Daniel Brungs(University of Wollongong), Katharine Cuff(Eastern Health), Wendy R. Parulekar(Unknown), Ehtesham Abdi, Alison Y. Zhang(The University of Sydney), Scott Williams(The University of Sydney), Karen Briscoe(Northern Cancer Institute), Alvin Tan(Royal Adelaide Hospital), Nicola Jane Lawrence(Australian National University), M. C. George(The University of Sydney), Kim Chi(BC Cancer Agency), Sean Bydder, Thean Hsiang Tan, Leanna Cheung(The University of Sydney), Suzanne Allan(Guy's Hospital)
Cited by 195
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
|The Lancet Oncology|2019|564
Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation
|Proceedings of the National Academy of Sciences|2014|403